Journal: Journal of Hematology & Oncology

Article Title: Downregulation of miR-130b~301b cluster is mediated by aberrant promoter methylation and impairs cellular senescence in prostate cancer

doi: 10.1186/s13045-017-0415-1

Figure Lengend Snippet: Differentially methylated microRNAs in prostate cancer. a Unsupervised hierarchical clustering of microRNAs’ promoters displaying significant alterations in DNA methylation as determined by Infinium HumanMethylation450 BeadChip in 25 prostate cancer (PCa) and 5 morphologically normal prostate tissue (MNPT) samples. Overall, 51 miRNA promoters were differentially methylated in PCa versus MNPT. b Validation of miR-130b~301b by pyrosequencing and ( c ) by RT-qPCR in 111 primary PCa and 14 MNPT cases, indicated that promoter hypermethylation was associated with miR-130b~301b downregulation. d LNCaP, DU145 and PC3 cell lines retain basal expression of miR-130b and miR-301b. e Reversal of DNA methylation in LNCaP cells using 5-aza-2-deoxycytidine (5-AZA-CdR) increased the expression of miR-130b and, in combination, with TSA augmented miR-301b expression. Mann-Whitney U test: * p < 0.05, ** p < 0.01, *** p < 0.001

Article Snippet: DNA methylation changes in microRNAs´ promoters in prostate cancer (PCa), determined by Infinium HumanMethylation450 BeadChip in 25 PCa tissues and 5 morphologically normal prostate tissue (MNPT) samples. (A) Schematic representation of the DNA methylation mapping approach used to identify new aberrantly methylated miRNAs. (B) β values from representative microRNAs. (C) Genomic location of the differentially methylated microRNAs. (D) DNA methylation levels determined by pyrosequencing in PCa cell lines, showing that all cell lines tested display aberrant DNA methylation in the promoter of miR-130b~301b cluster. (* p < 0.05, ** p < 0.01, *** p < 0.001).

Techniques: Methylation, DNA Methylation Assay, Quantitative RT-PCR, Expressing, MANN-WHITNEY